Oncolytic activity of HF10 in head and neck squamous cell carcinomas.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
09
04
2019
accepted:
07
06
2019
revised:
03
06
2019
pubmed:
4
9
2019
medline:
27
7
2021
entrez:
4
9
2019
Statut:
ppublish
Résumé
Recent developments in therapeutic strategies have improved the prognosis of head and neck squamous cell carcinoma (HNSCC). Nevertheless, 5-year survival rate remains only 40%, necessitating new therapeutic agents. Oncolytic virotherapy entails use of replication-competent viruses to selectively kill cancer cells. We aimed to explore the potential of HF10 as an oncolytic virus against human or mouse HNSCC cell lines, and primary-cultured HNSCC cells. HF10 replicated well in all the HNSCC cells, in which it induced cytopathic effects and cell killing. Next, we investigated the oncolytic effects of HF10 in ear tumor models with human or mouse tumor cells. We detected HF10-infected cells within the ear tumors based on their expression of green fluorescent protein. HF10 injection suppressed ear tumor growth and prolonged overall survival. In the syngeneic model, HF10 infection induced tumor necrosis with infiltration of CD8-positive cells. Moreover, the splenocytes of HF10-treated mice released antitumor cytokines, IL-2, IL-12, IFN-alpha, IFN-beta, IFN-gamma, and TNF-alpha, after stimulation with tumor cells in vitro. The HF10-treated mice that survived their original tumor burdens rejected tumor cells upon re-challenge. These results suggested that HF10 killed HNSCC cells and induced antitumoral immunity, thereby establishing it as a promising agent for the treatment of HNSCC patients.
Identifiants
pubmed: 31477804
doi: 10.1038/s41417-019-0129-3
pii: 10.1038/s41417-019-0129-3
pmc: PMC7445880
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
585-598Références
Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev. 2011;11:9–22.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
pubmed: 28055103
pmcid: 28055103
Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2015;45:884–91.
pubmed: 26142437
Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008;6:529–40.
pubmed: 18552863
pmcid: 3947522
Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5:e1115641.
pubmed: 26942095
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8.
pubmed: 26014293
Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17:718–30.
pubmed: 19915919
Watanabe D. Medical application of herpes simplex virus. J Dermatol Sci. 2010;57:75–82.
pubmed: 19939634
Fujimoto Y, Mizuno T, Sugiura S, Goshima F, Kohno S, Nakashima T, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol. 2006;126:1115–7.
pubmed: 16923721
Mace AT, Ganly I, Soutar DS, Brown SM. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck. 2008;30:1045–51.
pubmed: 18615711
Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010;16:4005–15.
pubmed: 20670951
Eissa IR, Naoe Y, Bustos-Villalobos I, Ichinose T, Tanaka M, Zhiwen W, et al. Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials. Front Oncol. 2017;7:149.
pubmed: 28770166
pmcid: 5509757
Mace AT, Harrow SJ, Ganly I, Brown SM. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Acta Otolaryngol. 2007;127:880–7.
pubmed: 17763002
Takaoka H, Takahashi G, Ogawa F, Imai T, Iwai S, Yura Y. A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma. Virol J. 2011;8:294.
pubmed: 21663640
pmcid: 3131258
Naito S, Obayashi S, Sumi T, Iwai S, Nakazawa M, Ikuta K, et al. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. Cancer Gene Ther. 2006;13:780–91.
pubmed: 16645620
Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther. 1999;10:1599–606.
pubmed: 10428205
Price DL, Lin SF, Han Z, Simpson G, Coffin RS, Wong J, et al. Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2010;136:151–8.
pubmed: 20157061
pmcid: 2824889
Yoo JY, Yu JG, Kaka A, Pan Q, Kumar P, Kumar B, et al. ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma. Mol Ther Oncolytics. 2015;2:15008.
pubmed: 27119105
pmcid: 4782961
Kim SH, Wong RJ, Kooby DA, Carew JF, Adusumilli PS, Patel SG, et al. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur J Cancer. 2005;41:313–22.
pubmed: 15661558
Yu Z, Adusumilli PS, Eisenberg DP, Darr E, Ghossein RA, Li S, et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther. 2007;15:103–13.
pubmed: 17164781
Yu Z, Li S, Huang YY, Fong Y, Wong RJ. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma. Cancer Gene Ther. 2007;14:738–47.
pubmed: 17525764
Meshii N, Takahashi G, Okunaga S, Hamada M, Iwai S, Takasu A, et al. Enhancement of systemic tumor immunity for squamous cell carcinoma cells by an oncolytic herpes simplex virus. Cancer Gene Ther. 2013;20:493–8.
pubmed: 23887644
Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther. 2002;13:1213–23.
pubmed: 12133274
Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg. 2001;193:12–21.
pubmed: 11442249
Wong RJ, Patel SG, Kim S, DeMatteo RP, Malhotra S, Bennett JJ, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther. 2001;12:253–65.
pubmed: 11177562
Takakuwa H, Goshima F, Nozawa N, Yoshikawa T, Kimata H, Nakao A, et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol. 2003;148:813–25.
pubmed: 12664303
Ushijima Y, Luo C, Goshima F, Yamauchi Y, Kimura H, Nishiyama Y. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microbes Infect. 2007;9:142–9.
pubmed: 17218138
Fujiwara S, Nawa A, Luo C, Kamakura M, Goshima F, Kondo C, et al. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther. 2011;18:77–86.
pubmed: 20885447
Descamps G, Wattiez R, Saussez S. Proteomic study of HPV-positive head and neck cancers: preliminary results. Biomed Res Int. 2014;2014:430906.
pubmed: 24719866
pmcid: 3955617
Sasai K, Fushiki M, Yukawa Y, Suyama S, Iwai H, Shibamoto Y, et al. In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation. Int J Radiat Oncol Biol Phys. 1991;21:1231–4.
pubmed: 1938521
Shibata T, Shibamoto Y, Oya N, Sasai K, Murata R, Ishigaki T, et al. Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses. Int J Radiat Oncol Biol Phys. 1994;29:587–90.
pubmed: 8005820
Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37:132–6.
pubmed: 9854077
pmcid: 84187
Esaki S, Goshima F, Katsumi S, Watanabe D, Ozaki N, Murakami S, et al. Apoptosis induction after herpes simplex virus infection differs according to cell type in vivo. Arch Virol. 2010;155:1235–45.
pubmed: 20535504
Esaki S, Goshima F, Kimura H, Ikeda S, Katsumi S, Kabaya K, et al. Auditory and vestibular defects induced by experimental labyrinthitis following herpes simplex virus in mice. Acta Otolaryngol. 2011;131:684–91.
pubmed: 21526906
Goshima F, Esaki S, Luo C, Kamakura M, Kimura H, Nishiyama Y. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer. Int J Cancer. 2014;134:2865–77.
pubmed: 24265099
Esaki S, Goshima F, Kimura H, Murakami S, Nishiyama Y. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. Int J Cancer. 2013;132:1592–601.
pubmed: 22949155
Hirst DG, Brown JM, Hazlehurst JL. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Br J Cancer. 1982;46:109–16.
pubmed: 7201845
pmcid: 2011076
Mery B, Rancoule C, Guy JB, Espenel S, Wozny AS, Battiston-Montagne P, et al. Preclinical models in HNSCC: a comprehensive review. Oral Oncol. 2017;65:51–6.
pubmed: 28109468
Mognetti B, Di Carlo F, Berta GN. Animal models in oral cancer research. Oral Oncol. 2006;42:448–60.
pubmed: 16266822
Schoop RA, Noteborn MH, Baatenburg deJongRJ. A mouse model for oral squamous cell carcinoma. J Mol Histol. 2009;40:177–81.
pubmed: 19685146
pmcid: 2770130
Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 2005;92:1341–8.
pubmed: 15846296
pmcid: 2361996
Chiocca EA. Oncolytic viruses. Nat Rev. 2002;2:938–50.
Kimata H, Takakuwa H, Goshima F, Teshigahara O, Nakao A, Kurata T, et al. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepatoastroenterology. 2003;50:961–6.
Kohno S, Luo C, Goshima F, Nishiyama Y, Sata T, Ono Y. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer. Urology. 2005;66:1116–21.
pubmed: 16286150
Kohno SI, Luo C, Nawa A, Fujimoto Y, Watanabe D, Goshima F, et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther. 2007;14:918–26.
pubmed: 17693992
Shimoyama S, Goshima F, Teshigahara O, Kasuya H, Kodera Y, Nakao A, et al. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Hepatogastroenterology. 2007;54:1038–42.
pubmed: 17629034
Teshigahara O, Goshima F, Takao K, Kohno S, Kimata H, Nakao A, et al. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J Surg Oncol. 2004;85:42–7.
pubmed: 14696086
Watanabe D, Goshima F, Mori I, Tamada Y, Matsumoto Y, Nishiyama Y. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci. 2008;50:185–96.
pubmed: 18226503
Tanaka R, Goshima F, Esaki S, Sato Y, Murata T, Nishiyama Y, et al. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model. Am J Cancer Res. 2017;7:1693–703.
pubmed: 28861325
pmcid: 5574941
Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, et al. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol. 2016;142:332–40.
pubmed: 27235858
pmcid: 4961516
Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593–623.
pubmed: 10358769
Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138–46.
pubmed: 8820272
Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev. 2012;12:298–306.
Czystowska M, Gooding W, Szczepanski MJ, Lopez-Abaitero A, Ferris RL, Johnson JT, et al. The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. Clin Cancer Res. 2013;19:889–99.
pubmed: 23363813
Ogawa M, Umehara K, Yu WG, Uekusa Y, Nakajima C, Tsujimura T, et al. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res. 1999;59:1531–8.
pubmed: 10197625
Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999;10:385–93.
pubmed: 10048391
Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000;7:867–74.
pubmed: 10845725
Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000;7:859–66.
pubmed: 10845724
Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373–9.
pubmed: 27486853
pmcid: 5084676